# A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

> **NCT05673785** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Takeda** · enrollment: 52 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05673785
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-10
- **Primary completion:** 2025-04-27
- **Final completion:** 2027-12-31
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673785, "A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05673785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*